Abstract
The spread of disease related to hepatitis B and C poses a significant public health problem. There have been a few studies that examine the effects of cohort and period on the trend of mortality caused by hepatitis B and C. This analysis aims to use an Age-Period-Cohort framework to explore trends in mortality attributed to hepatitis B and C worldwide and in different socio-demographic index (SDI) regions between 1990 and 2019. The data for this analysis were taken from the Global Burden of Disease (GBD) study, which was used to perform an age-period-cohort analysis. The age effects reflect differences in exposure to risk factors at different stages of life. The period effects reflect population-wide exposures at a circumscribed year. The cohort effects indicate different risks across birth cohorts. The results of the analysis include both the net drift and local drift, which are reported as the annual percentage change and that by age group. The age-standardized mortality rate (ASMR) for hepatitis B declined from 12.36 to 6.74 per 100,000, and for hepatitis C from 8.45 to 6.67 per 100,000 between 1990 and 2019. The net drifts in mortality were -2.41% (95% CI -2.47 to -2.34) for hepatitis B and -1.16% (95% CI, -1.23 to -1.09) for hepatitis C, with negative local drifts in most age groups. Mortality from hepatitis B increased with age until 50+ years, while mortality from hepatitis C rose steadily with age. The period effect for hepatitis B was profound, suggesting effective national efforts in controlling the disease and the need for similar programs for hepatitis B and C. Mortality varied across the world and had moderate to weak negative correlations with the SDI, which substantially decreases in the High-middle and Middle SDI regions, but has persistently high rates in the low SDI region. Global efforts to manage hepatitis B and C have shown positive trends, but variations in trends were observed across regions with divergent age, cohort, and period effects. The national efforts of a comprehensive strategy are crucial to further strengthen the elimination of hepatitis B and C. This article is protected by copyright. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.